A patent review of FGFR4 selective inhibition in cancer (2007-2018)-Reference-Cited by-同舟云学术

A patent review of FGFR4 selective inhibition in cancer (2007-2018)

Published:2019-05-30 Issue:6 Volume:29 Page:429-438
ISSN:1354-3776
Container-title:Expert Opinion on Therapeutic Patents
language:en
Short-container-title:Expert Opinion on Therapeutic Patents

Author:

Quintanal-Villalonga Alvaro¹,Ferrer Irene²³,Molina-Pinelo Sonia³⁴,Paz-Ares Luis²³⁵⁶

Affiliation:

1. Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

2. CNIO-H12O Lung Clinical Cancer Research Unit, Fundación de Investigación Biomédica i+12 & Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain

3. CIBERONC, Instituto de Salud Carlos III, Madrid, Spain

4. Instituto de Biomedicina de Sevilla (IBIS) (HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain

5. Medical Oncology Department, Hospital Universitario Doce de Octubre & Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain

6. Medical School, Universidad Complutense, Madrid, Spain

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543776.2019.1624720

Reference68 articles.

1. Roles of Fibroblast Growth Factor Receptors in Carcinogenesis

2. Fibroblast growth factor receptor 5 (FGFR5) is a co-receptor for FGFR1 that is up-regulated in beta-cells by cytokine-induced inflammation

3. The FGF family: biology, pathophysiology and therapy

4. De-regulated FGF receptors as therapeutic targets in cancer

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4;European Journal of Medicinal Chemistry;2024-03

2. Phytosterols Alleviate Hyperlipidemia by Regulating Gut Microbiota and Cholesterol Metabolism in Mice;Oxidative Medicine and Cellular Longevity;2023-04-26

3. Hydroxysteroid Dehydrogenase Like 2 Promotes the Invasion and Migration of Osteosarcoma by Regulating Fibroblast Growth Factor Receptor 4;Journal of Biomaterials and Tissue Engineering;2022-09-01

4. Many roads lead to Rome: The FGF4–AMP‐activated protein kinase–Caspase 6 signal axis in NAFLD and NASH;Hepatology;2022-03-25

5. Structure-based design of a dual-warhead covalent inhibitor of FGFR4;Communications Chemistry;2022-03-17